At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies.
The causes and consequences of tumour evolution and heterogeneity
15th October 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?